Physician profile
Madison Ramirez
NPI 1639840028
$617.15
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.16 · 2023: $497 · 2024: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.28 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $193.14 | 2023 | Mounjaro, Trulicity, Emgality |
| Abiomed | $102.84 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $67.96 | 2022-2023 | Farxiga, Breztri |
| Novo Nordisk INC | $67.08 | 2023 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $61.76 | 2023 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $32.44 | 2023 | Quviviq |
| Pfizer INC. | $23.58 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.25 | 2023 | Tradjenta, Jardiance |
| Alnylam Pharmaceuticals INC. | $17.20 | 2023 | Amvuttra |
| Phadia US INC. | $17.18 | 2023 | Immunocap |
| Dexcom, INC. | $14.72 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.